RNAi Capital Returns After Decade Gap but Pivotal Proof Still Pending

RNAi Developers See Resurgence in IPOs, VC, and M&A

The year 2026 has marked a significant resurgence in the biotech industry's interest and investment in RNA interference (RNAi) drug developers, following a decade of limited activity. This trend is characterized by a boom in initial public offerings (IPOs), substantial venture capital funding, and major mergers and acquisitions. Notably, ADARx Pharmaceuticals went public in September with a $446 million offering, the first RNAi developer IPO since 2014. City Therapeutics also listed on Nasdaq after securing $100 million in Series B funding, while AusperBio Therapeutics raised $120 million in a Series C round. Furthermore, Merck KGaA acquired Silence Therapeutics for over $1 billion, representing a 130% premium, signaling strong big pharma commitment to the RNAi space.

• After more than a decade of minimal activity, 2026 witnessed a significant revival in initial public offerings for RNAi drug developers. ADARx Pharmaceuticals spearheaded this trend, successfully launching on the Nasdaq in September with one of the year's largest offerings, raising $446 million. This marked the first RNAi drug developer to go public since 2014, signaling renewed investor confidence. City Therapeutics also secured a spot on the Nasdaq, contributing to the overall IPO boom for companies developing medicines with clinical potential or perceived superiority over existing therapies.
• Beyond public markets, RNAi startups attracted substantial venture capital, reflecting strong private investor buy-in. City Therapeutics, prior to its Nasdaq listing, raised $100 million in a Series B funding round. AusperBio Therapeutics secured an even larger investment, landing $120 million in a Series C round in August, making it the second-largest amount raised by an RNA drug startup this year. These significant capital injections demonstrate venture capitalists' increasing belief in the long-term potential and innovative platforms of emerging RNAi therapies.
• Large pharmaceutical companies have also made strategic, high-value bets on the RNAi sector through mergers and acquisitions. Merck KGaA notably acquired U.K.-based Silence Therapeutics for over $1 billion, a deal that offered a substantial 130% premium over Silence’s closing price. This acquisition represents the second-highest purchase premium among larger biopharma transactions in 2026, according to BioPharma Dive data. Analysts view such deals as a way for pharma to lock in value and mitigate execution risk, despite potential competition from existing therapies.

RNAi's Ascent: Emerging Mechanisms in Hereditary Angioedema

Recent literature describes evolution from non-specific treatments to targeted therapies addressing the kallikrein-kinin system and contact system. Investigational approaches focus on upstream inhibition, bradykinin signaling blockade, and durable reduction of plasma kallikrein production.

• Factor XII (FXII) / activated FXII (FXIIa) inhibition: Garadacimab, an FXIIa-targeted inhibitory monoclonal antibody, is described as approved for long-term prophylaxis against HAE attacks and administered subcutaneously (2 × 200 mg loading dose followed by 200 mg once monthly). FXII is described as the principal initiator of the contact system that ultimately regulates the kallikrein-kinin system, with activated FXII converting plasma prekallikrein to plasma kallikrein, which cleaves high-molecular-weight kininogen to produce bradykinin.

• Oral bradykinin B2 receptor antagonism for prophylaxis and on-demand treatment: Deucrictibant is described as an orally bioavailable bradykinin B2 receptor antagonist under development for prophylaxis and on-demand treatment, evaluated at 10 mg, 20 mg, or 30 mg for on-demand use and at 20 mg daily and 40 mg daily for 12 weeks for prophylaxis.

• Oral plasma kallikrein inhibition for on-demand treatment: Sebetralstat is described as an oral plasma kallikrein inhibitor in development for on-demand treatment of attacks, evaluated as a single 600 mg oral dose, with rapid absorption and near-complete protection from ex vivo stimulated generation of plasma kallikrein and cleavage of high-molecular-weight kininogen from 15 min to 4 h after administration in a subset of participants.

• Long-acting monoclonal antibody inhibition of plasma kallikrein: Navenibart (STAR-0215) is described as a monoclonal antibody inhibitor of plasma kallikrein modified to extend circulating half-life, with mean half-life ranging from 82 to 105 days for doses ≥300 mg and investigation for every-3-month and every-6-month administration to prevent attacks.

• Antisense-mediated reduction of plasma prekallikrein: Donidalorsen is described as a triantennary N-acetyl galactosamine-conjugated antisense oligonucleotide designed to specifically and reversibly reduce plasma prekallikrein production by binding to plasma prekallikrein messenger RNA in the liver, evaluated at 80 mg subcutaneously once every 4 weeks (Q4W) and once every 8 weeks (Q8W).

• CRISPR-Cas9 gene editing targeting KLKB1: NTLA-2002 is described as an investigational CRISPR-Cas9 gene-editing therapy targeting the KLKB1 gene to durably reduce plasma kallikrein levels, with preliminary trials demonstrating substantial reductions in HAE attack frequency and plasma kallikrein.

Addressing Unmet Needs in Hereditary Angioedema Treatment

Current treatment of hereditary angioedema is constrained by diagnostic delay, parenteral burden, and limited options for hereditary angioedema with normal C1 inhibitor. Delays to diagnosis have a direct impact upon patient suffering and quality of life, and long-term prophylaxis reduces but does not eliminate attacks.

• Diagnostic complexity in HAE with normal C1-INH limits targeted treatment: patients typically demonstrate normal plasma levels of C1-INH and complement component 4 protein and normal C1-INH functionality during laboratory analysis, genetic cause is still unknown in many cases, hindering full elucidation of the pathology of this HAE subtype, and diagnosis is delayed on average by almost a decade due to a misunderstanding of symptoms and general lack of awareness of the disease.

• Few evidence-based and licensed options for HAE-nC1-INH: HAE with normal C1 inhibitor is characterized by diagnostic challenges and limited evidence-based recommendations, knowledge about treatment strategies in HAE-nC1-INH remains insufficient, and most of the drugs are only licensed and approved for other types of HAE.

• Parenteral administration creates logistical and tolerability burden: available intravenous and subcutaneous treatments are accompanied by a significant treatment burden because of the logistical, emotional, and physical challenges posed by their long-term parenteral nature, including difficulty finding a usable vein or getting the infusion to work properly, injection site reactions, and administration-site adverse drug reactions such as site pain (17.9 reports per year), site erythema (7.4 per year), and site swelling (6.7 per year).

• Breakthrough attacks persist despite long-term prophylaxis: 30.1% of attacks occurred while patients were using long-term prophylaxis, respondents using C1-INH prophylaxis reported a mean of 2.3 attacks per month during the previous 6 months, and 82.5% of all breakthrough attacks were treated with a single icatibant injection without C1-INH rescue medication, supporting that patients using long-term prophylaxis should have emergency treatment readily available.

• Prophylactic alternatives involve efficacy and safety trade-offs: androgens are associated with significant adverse events and are not suitable for all patients, berotralstat was mainly associated with gastrointestinal adverse events (47.9%), while lanadelumab was linked to injection site reactions (45.9%), infections (23.3%), musculoskeletal and connective tissue disorders (10%), immune system disorders (5.3%), vascular disorders (4.7%), and metabolic issues (3.9%), and tranexamic acid demonstrated variable efficacy (2 of 10 achieved complete cessation, 5 of 10 partial reduction, and 3 of 10 no response).

• Emergency recognition and access barriers delay appropriate care: poor recognition of the bradykinin-dependent pathway leads to treatment errors in the emergency department, symptoms may perplex physicians when epinephrine, antihistamine, or glucocorticoid therapies do not provide relief, and pre-authorization and insurance coverage of HAE treatments affect burden of treatment for patients and caregivers.

Navigating the Competitive Landscape for RNAi in HAE

The knowledge base does not have sufficient information to answer this question.

RNAi's Resurgence: A Strategic Imperative for Pharma

The year 2026 has undeniably marked a watershed moment for RNA interference (RNAi) therapeutics, signaling a robust reawakening of investor and pharmaceutical industry confidence in this once-challenging modality. After a period characterized by limited activity, the current surge in initial public offerings, substantial venture capital infusions, and high-profile mergers and acquisitions paints a clear picture: RNAi is back in the spotlight, and this time, with significant financial backing.

The successful IPOs of companies like ADARx Pharmaceuticals and City Therapeutics, alongside substantial Series C funding for AusperBio Therapeutics, demonstrate a vibrant appetite in both public and private markets for innovative RNAi platforms. This influx of capital provides a critical runway for these developers to accelerate their preclinical and clinical pipelines, potentially bringing novel therapies to patients faster. For these companies, the strategic implication is clear: unprecedented opportunities for growth and market penetration.

Perhaps the most compelling signal of this resurgence is Merck KGaA's acquisition of Silence Therapeutics for over $1 billion, representing a staggering 130% premium. This move by a major pharmaceutical player is not merely an investment; it's a powerful validation of RNAi technology's perceived maturity and therapeutic potential. It underscores a strategic imperative for other big pharma entities to actively engage with or acquire RNAi capabilities to remain competitive in a rapidly evolving landscape. The modality itself is gaining significant visibility, which will likely attract further research and foster innovation in critical areas like delivery systems and target identification.

However, this renewed enthusiasm is not without its considerations. The 'decade of limited activity' that preceded this boom serves as a crucial reminder of the inherent scientific and clinical hurdles RNAi therapeutics have historically faced. While current investment suggests these challenges are being addressed, sustained success will depend on consistent clinical validation. Furthermore, the high premiums and rapid market expansion could introduce a risk of market overvaluation, particularly if early-stage assets fail to meet the elevated expectations of investors. The intensifying competitive landscape, with numerous players vying for leadership, also means that differentiation and robust clinical outcomes will be paramount for long-term success. The coming years will be critical in determining whether this resurgence translates into a sustained wave of transformative RNAi medicines.